Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study
A. Buisson, M. Nachury, M. Reymond, Clara Yzet, P. Wils, et al.. Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study. JOURNAL OF CROHNS & COLITIS, 2022, 16 (1), pp.I393-I394. ⟨hal-03665861⟩